OBJECTIVE: Vasoplegia syndrome after orthotopic heart transplantation (OHT) is a rare but highly lethal syndrome of unknown etiology, characterized by severe refractory hypotension, metabolic acidosis, and decreased systemic vascular resistance (SVR). The objective of this retrospective study was to identify the risk factors contributing to the development of vasoplegia syndrome after OHT in order to provide potential algorithms for its management. METHODS: Between October 1992 and July 2001, 187 consecutive patients underwent OHT. Complete pre- and post-data were available in 147 patients (78%). Mean age was 49+/-11 years, 82% (120/147) were male, and donor ischemic time was 117+/-62 min. Twenty-eight of 147 (19%) developed vasoplegia syndrome, defined as SVR <800 dyns per cm(5) with serum bicarbonate <20 mEq/l. RESULTS: Patients who developed vasoplegia syndrome demonstrated greater hospital mortality (25 vs. 9%, P=0.031) compared to those who did not. Multivariate logistic regression identified pre-operative use of intravenous heparin (OR 2.8, CI 1-7.4, P=0.039) and body surface area >1.9 m(2) (OR 7, CI 0.98-50, P=0.052) as independent predictors for the development of post-operative vasoplegia syndrome. Pre-operative use of inotropic support conferred protection against the development of post-operative vasoplegia syndrome (OR 0.25, CI 0.08-0.79, P=0.018). Pre-operative use of ACE inhibitors was not associated with increased risk (55 vs. 59%, P=0.441). CONCLUSIONS: Vasoplegia syndrome following OHT is associated with high early mortality. The development of a risk stratification profile may help in patient selection as well as the post-operative management of vasoplegia syndrome following OHT.
OBJECTIVE:Vasoplegia syndrome after orthotopic heart transplantation (OHT) is a rare but highly lethal syndrome of unknown etiology, characterized by severe refractory hypotension, metabolic acidosis, and decreased systemic vascular resistance (SVR). The objective of this retrospective study was to identify the risk factors contributing to the development of vasoplegia syndrome after OHT in order to provide potential algorithms for its management. METHODS: Between October 1992 and July 2001, 187 consecutive patients underwent OHT. Complete pre- and post-data were available in 147 patients (78%). Mean age was 49+/-11 years, 82% (120/147) were male, and donor ischemic time was 117+/-62 min. Twenty-eight of 147 (19%) developed vasoplegia syndrome, defined as SVR <800 dyns per cm(5) with serum bicarbonate <20 mEq/l. RESULTS:Patients who developed vasoplegia syndrome demonstrated greater hospital mortality (25 vs. 9%, P=0.031) compared to those who did not. Multivariate logistic regression identified pre-operative use of intravenous heparin (OR 2.8, CI 1-7.4, P=0.039) and body surface area >1.9 m(2) (OR 7, CI 0.98-50, P=0.052) as independent predictors for the development of post-operative vasoplegia syndrome. Pre-operative use of inotropic support conferred protection against the development of post-operative vasoplegia syndrome (OR 0.25, CI 0.08-0.79, P=0.018). Pre-operative use of ACE inhibitors was not associated with increased risk (55 vs. 59%, P=0.441). CONCLUSIONS:Vasoplegia syndrome following OHT is associated with high early mortality. The development of a risk stratification profile may help in patient selection as well as the post-operative management of vasoplegia syndrome following OHT.
Authors: J Hunter Mehaffey; Lily E Johnston; Robert B Hawkins; Eric J Charles; Leora Yarboro; John A Kern; Gorav Ailawadi; Irving L Kron; Ravi K Ghanta Journal: Ann Thorac Surg Date: 2017-05-24 Impact factor: 4.330
Authors: Lauren B Cooper; Robert J Mentz; Leah B Edwards; Amber R Wilk; Joseph G Rogers; Chetan B Patel; Carmelo A Milano; Adrian F Hernandez; Josef Stehlik; Lars H Lund Journal: J Heart Lung Transplant Date: 2016-07-17 Impact factor: 10.247
Authors: Chad E Wagner; Julian S Bick; Daniel Johnson; Rashid Ahmad; Xue Han; Jesse M Ehrenfeld; Jonathan S Schildcrout; Mias Pretorius Journal: Anesthesiology Date: 2014-03 Impact factor: 7.892
Authors: Jacob R Miller; Kathleen E Simpson; Deirdre J Epstein; Timothy S Lancaster; Matthew C Henn; Richard B Schuessler; David T Balzer; Shabana Shahanavaz; Joshua J Murphy; Charles E Canter; Pirooz Eghtesady; Umar S Boston Journal: J Heart Lung Transplant Date: 2016-03-10 Impact factor: 10.247
Authors: Kirsten A Kortekaas; Jan H N Lindeman; Marlies E J Reinders; Meindert Palmen; Robert J M Klautz; Philip G de Groot; Mark Roest Journal: Interact Cardiovasc Thorac Surg Date: 2013-06-04
Authors: Jason M Ali; Serena Patel; Pedro Catarino; Alain Vuylsteke; Stephen Pettit; Sai Bhagra; Anna Kydd; Clive Lewis; Jayan Parameshwar; Pradeep Kaul; Catherine Sudarshan; Steven Tsui; David Jenkins; Yasir Abu-Omar; Marius Berman Journal: J Thorac Dis Date: 2020-05 Impact factor: 2.895
Authors: Eric E C de Waal; Bas van Zaane; Marnix M van der Schoot; Albert Huisman; Faiz Ramjankhan; Wilton A van Klei; Nandor Marczin Journal: BMC Anesthesiol Date: 2018-12-08 Impact factor: 2.217